相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
Mario E. Lacouture et al.
ONCOLOGIST (2021)
Derazantinib: an investigational drug for the treatment of cholangiocarcinoma
Stephan Braun et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman et al.
CANCER DISCOVERY (2021)
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Gabriella Aitcheson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: Efficacy and molecular mechanisms of action, a comprehensive narrative review
Zahra Memariani et al.
PHARMACOLOGICAL RESEARCH (2021)
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma
Gentry King et al.
CURRENT ONCOLOGY REPORTS (2021)
Systemic therapies for intrahepatic cholangiocarcinoma
Robin Kate Kelley et al.
JOURNAL OF HEPATOLOGY (2020)
Naringin alleviates methotrexate-induced liver injury in male albino rats and enhances its antitumor efficacy in HepG2 cells
Hany Elsawy et al.
BIOSCIENCE REPORTS (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Pharmacokinetics and Metabolism of Naringin and Active Metabolite Naringenin in Rats, Dogs, Humans, and the Differences Between Species
Yang Bai et al.
FRONTIERS IN PHARMACOLOGY (2020)
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma
Chiara Raggi et al.
AMERICAN JOURNAL OF PATHOLOGY (2019)
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro et al.
BRITISH JOURNAL OF CANCER (2019)
Derazantinib for intrahepatic cholangiocarcinoma
Elizabeth Gourd
LANCET ONCOLOGY (2019)
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2018)
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype
Apurva Jain et al.
JCO PRECISION ONCOLOGY (2018)
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
K. P. Papadopoulos et al.
BRITISH JOURNAL OF CANCER (2017)
Anti-apoptotic and anti-inflammatory effects of naringin on cisplatin-induced renal injury in the rat
Yassine Chtourou et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2016)
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
Terence G. Hall et al.
PLOS ONE (2016)
Naringenin suppresses TPA-induced tumor invasion by suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells
Hung-Rong Yen et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2015)
Workshop Report: Crystal City V-Quantitative Bioanalytical Method Validation and Implementation: The 2013 Revised FDA Guidance
Brian Booth et al.
AAPS JOURNAL (2015)
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Sumera Rizvi et al.
GASTROENTEROLOGY (2013)
Mechanisms of Cisplatin Nephrotoxicity
Ronald P. Miller et al.
TOXINS (2010)
Effects of naringin on the pharmacokinetics of intravenous paclitaxel in rats
Sung-Cil Lim et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2006)
Metabolism of cisplatin to a nephrotoxin in proximal tubule cells
DM Townsend et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)